Business Development & Licensing


Vigorous Activities for Licensing Initiatives

We continue to forge ahead with licensing activities to introduce new drug candidates with the aim of introducing compounds attractive for diseases with high therapeutic need, and compounds that have high value in terms of corporate strategy and efficiency, while taking into consideration the development pipeline and existing products. Our aim is to expand the development pipeline to provide a continuous stream of new market launches. In the oncology domain, we take advantage of our strength with OPDIVO in acquiring product candidate compounds in a wide range of areas such as molecular target drugs including antitumor drugs and cell therapies.
In FY2017, we signed a license agreement with Array Biopharma (U.S.) to develop and commercialize the MEK inhibitor Binimetinib and the BRAF inhibitor Encorafenib in Japan and South Korea. We also signed a definitive agreement with Seikagaku Corporation on co-development and marketing collaboration on SI-613 in Japan, a drug under development by Seikagaku for osteoarthritis treatment (and also for enthesopathy treatment). In addition, we entered into an exclusive license agreement with Karyopharm Therapeutics (U.S.) to develop and commercialize the XPO1 inhibitor Selinexor and the second-generation XPO1 inhibitor KPT-8602, both under development by Karyopharm, in Japan, South Korea, Taiwan, Hong Kong, and ASEAN countries.
Meanwhile, we are keenly pursuing out-licensing activities to partner companies so that we can deliver new drugs we develop to patients worldwide. We have expanded collaboration activities with our long-time alliance partner Bristol-Myers Squibb (U.S.), granting the company the rights to develop and commercialize ONO-4578 under development by ONO—a selective antagonist of EP4 which is a Prostaglandin E2 (PGE2) receptor—worldwide, except Japan, South Korea, Taiwan, China and ASEAN countries.
By continuously and vigorously promoting licensing activities, we are making steady progress in expanding our development pipeline and developing a road map for global business to deliver the new drugs we develop.